Print Page     Close Window     

SEC Filings

8-K
SERES THERAPEUTICS, INC. filed this Form 8-K on 10/16/2017
Entire Document
 


Slide 21

SER-287 Phase 1b overall safety: most common (>5%) adverse events by treatment group Safety Population Preferred Term Placebo / Placebo (N = 11) n (%) Vancomycin / SER-287 daily (N = 15) n (%) Placebo / SER-287 weekly (N = 15) n (%) Vancomycin / SER-287 weekly (N = 17) n (%) SER-287 (N = 47) n (%) Treatment-Emergent Adverse Events (All) 7 (63.6) 8 (53.3) 9 (60.0) 14 (82.4) 31 (66.0) Abdominal pain 1 (9.1) 0 3 (20.0) 4 (23.5) 7 (14.9) Nausea 0 1 (6.7) 3 (20.0) 1 (5.9) 5 (10.6) Back pain 0 1 (6.7) 3 (20.0) 1 (5.9) 5 (10.6) Diarrhea 2 (18.2) 0 2 (13.3) 2 (11.8) 4 (8.5) Headache 0 3 (20.0) 0 1 (5.9) 4 (8.5) Constipation 0 2 (13.3) 1 (6.7) 0 3 (6.4) Flatulence 0 0 0 3 (17.6) 3 (6.4) Upper Respiratory Tract Infection 0 2 (13.3) 0 1 (5.9) 3 (6.4)


© Seres Therapeutics. All Rights Reserved.